[1] Thompson A J, Baranzini S E, Geurts J, et al.Multiple sclerosis[J].Lancet, 2018,391(10130):1622-1636. [2] Kim S H, Huh S Y, Kim W, et al.Clinical characteristics and outcome of multiple sclerosis in Korea:does multiple sclerosis in Korea really differ from that in the Caucasian populations?[J].Mult Scler, 2013,19(11):1493-1498. [3] Kavaliunas A, Manouchehrinia A, Stawiarz L, et al.Importance of early treatment initiation in the clinical course of multiple sclerosis[J].Mult Scler, 2017,23(9):1233-1240. [4] Marrie R A, Cutter G, Tyry T, et al.Changes in the ascertainment of multiple sclerosis[J].Neurology, 2005,65(7):1066-1070. [5] Thompson A J, Banwell B L, Barkhof F, et al.Diagnosis of multiple sclerosis:2017 revisions of the McDonald criteria[J].Lancet Neurol, 2018,17(2):162-173. [6] Barin L, Kamm C P, Salmen A, et al.How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis[J].Mult Scler,2020,26(4):489-500. [7] Polman C H, Reingold S C, Banwell B, et al.Diagnostic criteria for multiple sclerosis:2010 revisions to the McDonald criteria[J].Ann Neurol, 2011,69(2):292-302. [8] Miller D H, Leary S M.Primary-progressive multiple sclerosis[J].Lancet Neurol, 2007,6(10):903-912. [9] Jacobs L D, Wende K E, Brownscheidle C M, et al.A profile of multiple sclerosis:the New York State Multiple Sclerosis Consortium[J].Mult Scler, 1999,5(5):369-376. [10] Fernandez O, Fernandez V, Arbizu T, et al.Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study)[J].J Neurol, 2010,257(9):1500-1507. [11] Adamec I, Barun B, Gabelic T, et al.Delay in the diagnosis of multiple sclerosis in Croatia[J].Clin Neurol Neurosurg, 2013,115 Suppl 1:S70-72. [12] Chang K H, Lyu R K, Chen C M, et al.Clinical characteristics of multiple sclerosis in Taiwan:a cross-sectional study[J].Mult Scler, 2006,12(4):501-506. [13] Kim N H, Kim H J, Cheong H K, et al.Prevalence of multiple sclerosis in Korea[J].Neurology, 2010,75(16):1432-1438. [14] Kira J.Multiple sclerosis in the Japanese population[J].Lancet Neurol, 2003,2(2):117-127. [15] Scalfari A, Neuhaus A, Degenhardt A, et al.The natural history of multiple sclerosis:a geographically based study 10:relapses and long-term disability[J].Brain, 2010,133(Pt 7):1914-1929. [16] Hsueh C J, Kao H W, Chen S Y, et al.Comparison of the 2010 and 2005 versions of the McDonald MRI criteria for dissemination-in-time in Taiwanese patients with classic multiple sclerosis[J].J Neurol Sci, 2013,329(1-2):51-54. [17] Selchen D, Bhan V, Blevins G, et al.MS, MRI, and the 2010 McDonald criteria:a Canadian expert commentary[J].Neurology, 2012,79(23 Suppl 2):S1-15. [18] Solomon A J, Weinshenker B G.Misdiagnosis of multiple sclerosis:frequency, causes, effects, and prevention[J].Curr Neurol Neurosci Rep, 2013,13(12):403. [19] Wingerchuk D M, Banwell B, Bennett J L, et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J].Neurology, 2015,85(2):177-189. [20] Pandit L, Asgari N, Apiwattanakul M, et al.Demographic and clinical features of neuromyelitis optica:a review[J].Mult Scler, 2015,21(7):845-853. [21] Trebst C, Jarius S, Berthele A, et al.Update on the diagnosis and treatment of neuromyelitis optica:recommendations of the Neuromyelitis Optica Study Group (NEMOS)[J].J Neurol, 2014,261(1):1-16. [22] Zekeridou A, Lennon V A.Aquaporin-4 autoimmunity[J].Neurol Neuroimmunol Neuroinflamm, 2015,2(4):e110. [23] Pittock S J, Lennon V A, Bakshi N, et al.Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis[J].JAMA Neurol, 2014,71(11):1433-1436. |